The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer

BJU International

Volumn 102, Issue 6, 2008, Pages 756-761

  Lamb, Gavin W A ^b   McArdle, Peter A ^a   Ramsey, Sara ^b   McNichol, Anne Marie ^a   Edwards, Joanne ^a   Aitchison, Michael ^b   McMillan, Donald C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cancer specific survival; Grade; Nephrectomy; Performance status; Renal cancer; Systemic inflammatory response; Tumour stage

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2; INTERLEUKIN 6 RECEPTOR;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 50049104392     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07666.x     Document Type: Article

References (53)

1. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001 85 : 473 83
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 420 : 860 7
3. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004 4 : 641 8
4. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000 37 : 36 40
5. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001 41 : 64 9
6. Maltoni M, Caraceni A, Brunelli C et al. Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005 23 : 6240 8
7. Blay JY, Negrier S, Combarlet V et al. Serum level of Il-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992 52 : 3317 22
8. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003 88 : 348 53
9. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha interferon treatment for advanced renal cancer. Br J Cancer 2004 91 : 1238
10. Casamassima A, Picciarello M, Quaranta M et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell cancer treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005 173 : 52 5
11. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation based prognostic score in patients with metastatic renal cancer. Cancer 2007 109 : 205 12
12. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003 90 : 215 9
13. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003 238 : 197 202
14. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005 92 : 625 7
15. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration prior to surgery predicts poor cancer specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006 94 : 1568 71
16. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998 5 : 418 22
17. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the pre-operative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006 94 : 781 4
18. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumour proliferative activity in patients with colorectal carcinoma. Cancer 1999 85 : 2526 31
19. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004 91 : 1993 5
20. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001 20 : 198 208
21. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003 9 : 4653 65
22. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998 69 : 248 52
23. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004 30 : 261 77
24. Canna K, McArdle PA, McMillan DC et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005 92 : 651 4
25. Costes V, Liautard J, Picot MC et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997 50 : 835 40
26. Nakano O, Sato M, Naito Y et al. Proliferation activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathological demonstration of antitumour immunity. Cancer Res 2001 61 : 5132 6
27. Bromwich EJ, McArdle PA, Canna K et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell carcinoma. Br J Cancer 2003 89 : 1906 8
28. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subaramaiah K. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001 2 : 544 51
29. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003 24 : 96 102
30. Fosslien E. Molecular pathology of cyclo-oxygenase-2 in neoplasia. Ann Clin Lab Sci 2000 30 : 3 21
31. McMillan DC, Leen E, Smith J et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1995 21 : 531 4
32. Shimizu C, Kubo M, Takano K et al. Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs. Clin Endocrinol 2001 54 : 405 10
33. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000 60 : 5488 93
34. Harris RC. Interactions between COX-2 and the renin-angiotensin system in the kidney. Acta Physiol Scand 2003 177 : 423 7
35. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003 9 : 1741 9
36. Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology 2004 64 : 1116 20
37. Sobin L, Wittekind C eds. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors, 5th edn. New York : Wiley-Liss, 1997 : 180 2
38. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982 6 : 655 63
39. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. HER2 and COX2 expression in human prostate cancer. Eur J Cancer 2004 40 : 50 5
40. Wendrum D, Svrcek M, Rigau V et al. COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol 2003 16 : 130 6
41. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative C-reactive protein level predicts a poor prognosis in patient with localised renal cell carcinoma. BJU Int 2007 99 : 77 80
42. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein on the prognosis for patients with renal cell carcinoma. Int J Urol 2006 13 : 1365 70
43. O'Reilly DS, Upton MN, Caslake MJ et al. Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. Heart 2006 92 : 533 5
44. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999 340 : 448 54
45. Takenawa J, Kawenko Y, Fukumoto M et al. Enhanced expression of interleukin-6 in primary human renal cell carcinoma. J Natl Cancer Inst 1991 83 : 1668 72
46. Paule B, Belot J, Rudant C, Coulombel C, Abbou CC. The importance of Il-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol 2000 53 : 388 90
47. Yoshida N, Ikemoto S, Narita K et al. Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma. Br J Cancer 2002 86 : 1396 400
48. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006 2 : 619 6
49. Siddiqui SA, Frigola X, Bonne-Annee S et al. Tumour infiltrating Foxp 3-CD4+CD25+ T cells predicts poor survival in renal cell carcinoma. Clin Cancer Res 2007 13 : 2075 81
50. Hashimoto Y, Kondo Y, Kimura G et al. Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 2004 44 : 353 9
51. Cho DS, Joo HJ, Oh DK et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 2005 46 : 133 40
52. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/ supportive care. J Support Oncol 2007 5 : 157 62
53. Jabs WJ, Busse M, Krüger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005 68 : 2103 10